Phase 2/3Status unknown
Previfenon® as Chemoprophylaxis of COVID-19 in Health Workers (HERD)
A Multicenter, Double-blind, Randomized, Placebo-controlled Clinical Trial to Protect Health Workers Against COVID-19 by Using Previfenon® as Chemoprophylaxis During a SARS-CoV-2 Outbreak. The HERD Study
- Sponsor
- MELISA Institute Genomics & Proteomics Research SpA (Industry)
- Enrolment
- 524 planned
- Conditions
- COVID-19; SARS-CoV2
- Interventions
- Previfenon®; Placebo
- Ages
- adults, older adults
- Registry
- NCT04446065
Full record on ClinicalTrials.gov
From the registry
The purpose of this clinical trial is to determine the efficacy of Previfenon® (EGCG) to prevent COVID-19, enhance systemic immunity, and decrease the frequency and intensity of selected symptoms when used as pre-exposure chemoprophylaxis to SARS-CoV-2.
Primary outcomes
- Event of clinical acute respiratory disease with a diagnosis of COVID-19 confirmed with rtPCR
History
Study completion
Primary completion
Started
Last registry update
Registered